Company: ABBV
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001551152-25-000029
Chunk: 16

Company: AbbVie Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 and $1 for the three months ended March 31, 2024(2)10 Cash flow hedging activities, net of tax expense (benefit) of $(4) for the three months ended March 31, 2025 and $7 for the three months ended March 31, 2024(19)30 Other comprehensive income (loss)183 (149)Comprehensive income1,472 1,223 Comprehensive income attributable to noncontrolling interest3 3 Comprehensive income attributable to AbbVie Inc.$1,469 $1,220 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2025 Form 10-Q | 2

AbbVie Inc. and Subsidiaries Condensed Consolidated Balance Sheets 

(in millions, except share data)March 31,2025December 31, 2024(unaudited)AssetsCurrent assetsCash and equivalents$5,175 $5,524 Short-term investments1 31 Accounts receivable, net12,477 10,919 Inventories4,526 4,181 Prepaid expenses and other5,496 4,927 Total current assets27,675 25,582 Investments287 279 Property and equipment, net5,237 5,134 Intangible assets, net58,489 60,068 Goodwill35,285 34,956 Other assets9,192 9,142 Total assets$136,165 $135,161 Liabilities and EquityCurrent liabilitiesShort-term borrowings$1,593 $— Current portion of long-term debt and finance lease obligations3,769 6,804 Accounts payable and accrued liabilities31,041 31,945 Total current liabilities36,403 38,749 Long-term debt and finance lease obligations64,527 60,340 Deferred income taxes2,582 2,579 Other long-term liabilities31,191 30,129 Commitments and contingenciesStockholders' equityCommon stock, $0.01 par value, 4,000,000,000 shares authorized, 1,837,071,074 shares issued as of March 31, 2025 and 1,831,594,494 as of December 31, 202418 18 Common stock held in treasury, at cost, 70,782,